Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is not a commercial combination product but refers to the co-administration of tetanus-diphtheria-acellular pertussis (Tdap) vaccine and human papillomavirus (HPV) vaccine, sometimes with placebo in clinical trial settings. The CDC promotes a "bundling approach" for adolescent vaccines, where Tdap and HPV vaccines are administered during the same clinical visit but at separate injection sites. Studies have shown that adolescents who receive their first HPV vaccine bundled with the Tdap vaccine are 45% more likely to complete the HPV vaccine series compared to those who receive it alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + tetanus-diphtheria-acellular pertussis vaccine + human papillomavirus vaccine.